Blocking Monoclonal Antibodies Against a GPCR Target


Genovac was interested in pursuing an internal campaign to develop a functional, antagonistic antibody against a GPCR protein called human FPR2 (N-formyl peptide receptor 2), also known as FPRL1 (N-formyl peptide receptor-like 1). This target is challenging because it is a multi-transmembrane spanning protein with relatively small extracellular N-terminal domains.


To learn more about how Genovac discovered blocking antibodies against the challenging target FPR2 and to view more data about our methodology and results, click on the downloadable PDF link below to access our full case study.